Low frequency, weak MCP-1 secretion and exhausted immune status of peripheral monocytes were associated with progression of severe enterovirus A71-infected hand, foot and mouth disease.
Antibodies, Blocking
/ metabolism
B7-H1 Antigen
/ metabolism
Biomarkers
/ blood
Cells, Cultured
Cellular Senescence
Chemokine CCL2
/ blood
Child
Child, Preschool
Cohort Studies
Disease Progression
Enterovirus A, Human
/ physiology
Female
Hand, Foot and Mouth Disease
/ diagnosis
Humans
Immunity, Cellular
Infant
Leukocyte Count
Male
Monocytes
/ immunology
Programmed Cell Death 1 Receptor
/ metabolism
Severity of Illness Index
Signal Transduction
enterovirus A71 (EV-A71)
foot and mouth disease (HFMD)
hand
monocyte
monocyte chemoattractant protein-1 (MCP-1)
programmed cell death-1 (PD-1)
Journal
Clinical and experimental immunology
ISSN: 1365-2249
Titre abrégé: Clin Exp Immunol
Pays: England
ID NLM: 0057202
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
accepted:
14
01
2019
pubmed:
31
1
2019
medline:
4
4
2020
entrez:
31
1
2019
Statut:
ppublish
Résumé
A minority of hand, foot and mouth disease (HFMD) caused by enterovirus A71 (EV-A71) results in severe neural complications. However, whether monocyte-mediated immunity is involved in the disease progression of HFMD remains unknown. One hundred and twenty mild and 103 severe HFMD patients were recruited and enzyme-linked immunosorbent assay (ELISA), flow cytometry and Transwell culture were performed in the study. Peripheral monocyte counts were lower in both absolute counts and frequencies in severe cases compared to mild cases. After screening 10 monocyte-related cytokines by ELISA, only monocyte chemoattractant protein-1 (MCP-1) was found at higher levels in sera of mild cases compared to those with severe symptoms. Monocytes purified from mild cases produced more MCP-1 than the cells from severe patients when stimulated in vitro. We observed that immune exhaustion markers programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) were highly regulated on the surface of monocytes from severe cases compared to mild cases. PD-L1 blockade induced a higher production of MCP-1 in the supernatant of a Transwell system. The production of MCP-1 also increased following PD-L1 blockade of purified monocytes activated by granulocyte-macrophage colony-stimulating factor (GM-CSF) combined with R848 or EV-A71 virus. Our results indicate that absolute count, frequency and levels of MCP-1 secretion of peripheral monocytes, together with their immune status, probably contribute to differential disease prognosis in EV-A71-associated HFMD.
Identifiants
pubmed: 30697697
doi: 10.1111/cei.13267
pmc: PMC6514369
doi:
Substances chimiques
Antibodies, Blocking
0
B7-H1 Antigen
0
Biomarkers
0
CCL2 protein, human
0
Chemokine CCL2
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
353-363Informations de copyright
© 2019 British Society for Immunology.
Références
Pediatrics. 2002 Jun;109(6):e88
pubmed: 12042582
Microcirculation. 2003 Jun;10(3-4):247-57
pubmed: 12851642
J Infect Dis. 2003 Aug 15;188(4):564-70
pubmed: 12898444
J Virol. 2004 Jun;78(12):6449-58
pubmed: 15163738
Nat Rev Immunol. 2004 Oct;4(10):812-23
pubmed: 15459672
Pediatr Res. 2006 Oct;60(4):466-71
pubmed: 16940249
J Infect Dis. 2008 Oct 1;198(7):1002-6
pubmed: 18710325
Exp Biol Med (Maywood). 2009 Oct;234(10):1166-73
pubmed: 19596831
Gastroenterology. 2010 Feb;138(2):682-93, 693.e1-4
pubmed: 19800335
Clin Chim Acta. 2010 Nov 11;411(21-22):1570-9
pubmed: 20633546
Cytokine. 2010 Dec;52(3):175-83
pubmed: 20650649
J Virol. 2011 Apr;85(7):3067-76
pubmed: 21228224
Infect Immun. 2012 Dec;80(12):4099-105
pubmed: 22966045
J Exp Med. 2013 Apr 8;210(4):757-74
pubmed: 23530125
Nat Immunol. 2013 Aug;14(8):821-30
pubmed: 23812096
Immunity. 2014 Jan 16;40(1):13-24
pubmed: 24439265
Cell Mol Immunol. 2014 May;11(3):294-304
pubmed: 24531620
Nat Rev Immunol. 2014 Jun;14(6):392-404
pubmed: 24854589
Cell Mol Immunol. 2015 Jul;12(4):435-43
pubmed: 25109683
AIDS. 2014 Sep 24;28(15):2175-87
pubmed: 25144219
Cleve Clin J Med. 2014 Sep;81(9):537-43
pubmed: 25183845
BMC Cancer. 2014 Oct 03;14:744
pubmed: 25280428
Expert Rev Vaccines. 2015 Mar;14(3):337-40
pubmed: 25536888
J Appl Microbiol. 2015 Oct;119(4):1196-205
pubmed: 26248815
Viruses. 2015 Dec 14;7(12):6613-30
pubmed: 26694447
Med Microbiol Immunol. 2016 Oct;205(5):397-407
pubmed: 27406374
Sci Rep. 2016 Aug 25;6:32288
pubmed: 27558873
Int J Environ Res Public Health. 2016 Sep 09;13(9):
pubmed: 27618078
N Engl J Med. 2016 Nov 3;375(18):1767-1778
pubmed: 27806234
Ann Oncol. 2018 Feb 1;29(2):517-518
pubmed: 29206889
Front Immunol. 2017 Dec 05;8:1693
pubmed: 29259605
Sci Rep. 2018 Jan 26;8(1):1658
pubmed: 29374213
Immunology. 1988 Aug;64(4):733-8
pubmed: 2971612